Bio-Rad Antibodies’ Post

ATR inhibition is a promising strategy for cancer therapeutics. At Aprea, we are developing ATRN-119, a differentiated macrocyclic and highly selective, potent, oral ATR inhibitor with antitumor activity. Preliminary results of our ongoing first-in-human study of ATRN-119 were presented recently at the ENA conference. Learn more about Aprea’s pipeline: https://lnkd.in/gtx7gTTK #PrecisionOncology #Data #ClinicalTrials 

🚨 Major breakthrough! The FDA has approved Zihera, a groundbreaking cancer-treating antibody developed by Vancouver-based biotech company Zymeworks! 🎉 This approval marks a huge milestone for treating metastatic HER2-positive biliary tract cancer—a rare and deadly form of GI cancer. This game-changing treatment offers hope where chemotherapy has failed, showing significant tumor shrinkage in clinical trials. 🧬💡 We’re celebrating this success and the incredible innovations coming out of Canada’s biotech sector. 🌍👏 Read More: https://lnkd.in/gygUvQw5 #PharmaInnovation #FDAApproval #CancerResearch #Zymeworks #Biotech #TorontoInstituteOfPharmaceuticalTechnology #MedicalBreakthroughs #Her2Positive #HealthTech

At Cortalix we are developing CTX001, a single-domain antibody to target the PDGF beta Receptor (CD140b) in fibrosis and cancer. See why the PDGF beta Receptor is such an interesting novel radiopharmaceutical target.   #PETimaging #TRT #singledomainantibody #nanobody #PDGFR #CD140b

Exciting developments from GRAIL in multi-cancer early detection and precision medicine! At PMWC 2025 NEXT WEEK, we’ll dive deeper into MCED innovations during the "Multi-Cancer Early Detection: Innovations and Real-World Evidence (PANEL)" session, chaired by Peter B. (Bach) from DELFI Diagnostics Join Eric A. Klein, MD (GRAIL Bio), along with experts from Haystack, Exact Sciences, and BLOODPAC, as we discuss the latest advances in ctDNA and pre-surgical analysis for NSCLC. Looking forward to exploring how GRAIL’s technology is advancing cancer screening and precision treatments!

Now available to view on demand! Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges for project teams. In our latest webinar, experts discuss methodologies for evaluating ADC efficacy, resistance, and immunogenicity that address both antibody-specific and payload-specific mechanisms through various multi-dimensional assays. This webinar offers a comprehensive perspective on strategies and approaches that are crucial for accelerating research focused on antibody-drug conjugates. Click 👇 this link to view the video: https://ow.ly/IGpm50UIPgI #DrugDiscovery #DrugDevelopment #ADCs #Antibody #Conjugates #Immunogenicity

Prostate cancer is the second most common cancer in men globally, with over 1.4 million cases reported in 2020. Early-stage survival rates are high, but significantly decline in advanced stages, highlighting the need for more effective treatments. A recent study using our TRC research chemicals identified the enzyme 2,4-dienoyl CoA reductase 2 (DECR2) as a promising therapeutic target. When combined with standard androgen receptor inhibitors, depletion of the DECR2 enzyme showed potential in treating preclinical models of castration-resistant prostate cancer. Read the full study in the British Journal of Cancer: https://okt.to/AXjC1Z 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/vn52O1 #ProstateCancer #oncology #oncologyresearch #ResearchChemicals

🚨 The Future of Oncology: Next-Gen ADCs are Here! 🧬 Antibody-drug conjugates (ADCs) are entering their golden age, revolutionising cancer treatment by combining targeted therapy with potent cytotoxic drugs. This $12B market is projected to hit $44B by 2029! 🚀 Highlights: 🔬 Advanced payload & linker tech is widening therapeutic windows. 💊 ZAI Lab, Sutro Biopharma, Inc., and ADC Therapeutics are leading innovation. 💡 Beyond cancer: ADCs could tackle autoimmune diseases in the future! #Oncology #ADCTherapeutics #Biotech #CancerCare #Innovation

Read the Editorial Commentary on MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations by Edyta Maria Urbanska, Jens Mollerup, and Jan Trøst Jørgensen and recently published in Translational Lung Cancer Research (Open Access): https://lnkd.in/dM5F5KvZ #medicine #pharmaceuticals #oncology #precisionmedicine #biomarkers

Did you know? #Therapeutics for #oncology often work for some time until inevitably resistance to the drug develops. The #cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs. Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again. NYSE: KAPA #KairosPharma #CancerTreatment #HealthcareInnovation #BioTech #PharmaTech #BioTechStock #PharmaStock #NYSE

Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment